Pharmaceuticals in U.S. Health Care: Determinants of Quantity and Price
- 1 November 2002
- journal article
- Published by American Economic Association in Journal of Economic Perspectives
- Vol. 16 (4), 45-66
- https://doi.org/10.1257/089533002320950975
Abstract
The U.S. pharmaceutical industry has again become the focus of considerable controversy. In understanding the economics underlying this industry, distinctions between short, medium and long-run costs are critical, as is that between economic and accounting costs. Consumers' heterogeneous valuations create strong incentives for non-uniform pricing and targeted marketing. The conflict between static efficiency (price new drugs low, near short-run marginal cost) and dynamic efficiency (price new drugs high, maintain incentives for innovation) is deep and enduring. This trade-off is becoming more severe as the relative costs of bringing new drugs to market have increased sharply.Keywords
This publication has 15 references indexed in Scilit:
- The medical treatment of depression, 1991–1996: productive inefficiency, expected outcome variations, and price indexesJournal of Health Economics, 2001
- Prescription Drug Prices: Why Do Some Pay More Than Others Do?Health Affairs, 2001
- The U.S. Pharmaceutical Industry: Why Major Growth In Times Of Cost Containment?Health Affairs, 2001
- Comparing SSRI Treatment Costs for Depression Using Retrospective Claims Data: The Role of Nonrandom Selection and Skewed DataValue in Health, 2000
- International comparisons of pharmaceutical prices: what do we know, and what does it mean?Journal of Health Economics, 2000
- Cross-national price differences for pharmaceuticals: how large, and why?Journal of Health Economics, 2000
- The importance of the physician in the generic versus trade-name prescription decision.The RAND Journal of Economics, 1998
- Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EUInternational Journal of the Economics of Business, 1997
- The Distribution and Pricing of Prescription DrugsInternational Journal of the Economics of Business, 1997
- Longer Patents for Increased Generic Competition in the USPharmacoEconomics, 1996